Schizophrenia and Related Disorders Clinical Trial
Official title:
TMS for Symptom Reduction in Schizophrenia
To test the hypothesis that functionally navigated repetitive TMS stimulations to the prefrontal cortex (PFC) modulate aberrant cortical electrical activities at PFC circuitry. The TMS location of the PFC site will be individually localized by the symptom-related functional connectivity between PFC and symptom related areas (such as the auditory and language processing cortex). The investigators predict that such modulation will correct abnormal activities in patients with schizophrenia, reduce symptoms, especially auditory hallucination, and improve working memory/sustained attention performance.
Neuroimaging studies suggest that aberrant activities at specific brain regions such as sensory areas and language-related areas are related to psychosis symptoms including auditory and visual hallucination, delusion, and thought disorders. Transcranial magnetic stimulation (TMS) provides a non-invasive means for altering brain electrical neural activity. TMS has been approved by FDA for treatment of depression. Other applications have not been approved but it has been used in a wide range of clinical research especially in neurology and psychiatry. Among psychotic symptoms, there are preliminary significant improvement in treatments of auditory hallucination using TMS with small samples, but those treatments are not robust in larger samples. The high inter-subject variability limits the efficacy of TMS treatment in schizophrenia patients. The investigators aim to develop a TMS treatment method with a fMRI-defined treatment target area, where the TMS target is individually identified to maximize the TMS effects. The identification method uses both the anatomical character and its functional relationship with auditory hallucination and other psychosis symptoms. If the current target-identification successfully identified effective TMS target individually, the treatment efficacy will be significant improved and more patients will benefit from TMS treatment. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT05083377 -
Clozapine Use Pattern in the Province of Seville
|
||
| Recruiting |
NCT06313918 -
Exercise Therapy in Mental Disorders-study
|
N/A | |
| Recruiting |
NCT06134661 -
Accelerated rTMS for Psychomotor Slowing
|
N/A | |
| Completed |
NCT01433094 -
Study on Psychoeducation Enhancing Results of Adherence in Schizophrenia
|
N/A | |
| Terminated |
NCT05526833 -
An Extension Protocol for Patients Who Previously Completed the TMS Pilot Study
|
N/A | |
| Recruiting |
NCT05982158 -
Avatar-mediated Therapy Versus Cognitive Behavioural Therapy for Persisting Experiences of Hearing Voices
|
N/A | |
| Active, not recruiting |
NCT06175559 -
Embedded Narrative in Interactive Game Design for Improving Medication Adherence of Schizophrenia
|
N/A | |
| Active, not recruiting |
NCT05673941 -
"InMotion" - Physical Training With Creative Movement as an Intervention for Adults With Schizophrenia
|
N/A | |
| Recruiting |
NCT05958875 -
The Effect of a Six Week Intensified Pharmacological Treatment for Schizophrenia Compared to Treatment as Usual in Subjects Who Had a First-time Treatment Failure on Their First-line Treatment.
|
Phase 4 | |
| Recruiting |
NCT03525054 -
Semantic and Syntactic Computerized Analysis of Free Speech
|
||
| Recruiting |
NCT05389345 -
tDCS and Executive Function Training for Schizophrenia
|
N/A | |
| Completed |
NCT05601050 -
Linguistic Predictors of Outcomes in Psychosis
|
||
| Completed |
NCT03075202 -
Role of an E-cigarette on Smoking Displacement in Smokers With Schizophrenia
|
||
| Completed |
NCT03921450 -
Overcoming Psychomotor Slowing in Psychosis (OCoPS-P)
|
N/A | |
| Completed |
NCT06231407 -
Increasing Medication Check Participation Through Applying CT-r
|
N/A | |
| Recruiting |
NCT04478838 -
"Extended" (Alternate Day) Antipsychotic Dosing
|
Phase 4 | |
| Completed |
NCT04366401 -
Efficacy of Prebiotic and Probiotic Dietary Modulation in Schizophrenic Disorders
|
N/A | |
| Completed |
NCT04612777 -
A Trial of "Opening Doors to Recovery" for Persons With Serious Mental Illnesses
|
N/A | |
| Not yet recruiting |
NCT06191965 -
MitoQ for Early-phase Schizophrenia-spectrum Disorder and Mitochondrial Dysfunction
|
Phase 2/Phase 3 | |
| Recruiting |
NCT04321759 -
Comparative Effectiveness of CET vs. SST in SMI (Serious Mental Illness)
|
N/A |